SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    GovindanR, PageN, MorgenszternD, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol. 2006; 24: 4539-4544.
  • 2
    BaymanaNA, SheikhaH, KularatnebB, et al. Radiotherapy for small-cell lung cancer—where are we heading? Lung Cancer. 2009; 63: 307-314.
  • 3
    KomakiR. Combined treatment for limited small cell lung cancer. Semin Oncol. 2003; 30( suppl 9): 56-70.
  • 4
    O'BrienME, CiuleanuTE, TsekovH, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006; 24: 5441-5447.
  • 5
    AllenJ, JahanzebM. Extensive-stage small-cell lung cancer: evolution of systemic therapy and future directions. Clin Lung Cancer. 2008; 9: 262-270.
  • 6
    EckertF, MullerAC. SCLC-extensive disease. Treatment guidance by extent or/and biology of response [serial online]? Radiat Oncol. 2008; 3: 33.
  • 7
    JeremicB, ShibamotoY, NikolicN, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999; 17: 2092-2099.
  • 8
    LoehrerPJ Sr, AnsariR, GoninR, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol. 1995; 13: 2594-2599.
  • 9
    SundstromS, BremnesRM, KaasaS, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002; 20: 4665-4672.
  • 10
    KobayashiM, MatsuiK, IwamotoY, et al. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301. J Thorac Oncol. 2010; 5: 1075-1080.
  • 11
    PignonJP, ArriagadaR, IhdeDC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992; 327: 1618-1624.
  • 12
    WardeP, PayneD. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992; 10: 890-895.
  • 13
    ZelenM. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep. 1973; 4: 31-42.
  • 14
    SlotmanB, Faivre-FinnC, KramerG, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007; 357: 664-672.
  • 15
    OuSH, ZiogasA, ZellJA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol. 2009; 4: 37-43.
  • 16
    YeeD, ButtsC, ChuQ, et al. Phase II trial of consolidation chest radiotherapy for extensive stage small cell lung cancer [abstract]. Radiother Oncol. 2010; 96( suppl 1): 1021.
  • 17
    TakadaM, FukuokaM, KawaharaM, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002; 20: 3054-3060.